Regulation of HIF-1 by MicroRNAs in Various Cardiovascular Diseases

Overview

Journal Curr Cardiol Rev

Publisher Bentham Science Publishers

Specialty Cardiology & Vascular Diseases

Date 2023 Apr 3

PMID 37005512

Authors

Vahideh Tarhriz

Leila Abkhooie

Mostafa Moradi Sarabi

Affiliations

Soon will be listed here.

Abstract

Today, we see an increase in death due to cardiovascular diseases all over the world, which has a lot to do with the regulation of oxygen homeostasis. Also, hypoxia-inducing factor 1 (HIF-1) is considered a vital factor in hypoxia and its physiological and pathological changes. HIF- 1 is involved in cellular activities, including proliferation, differentiation, and cell death in endothelial cells (ECs) and cardiomyocytes. Similar to HIF-1α, which acts as a protective element against various diseases in the cardiovascular system, the protective role of microRNAs (miRNAs) has also been proved using animal models. The number of miRNAs identified in the regulation of gene expression responsive to hypoxia and the importance of investigating the involvement of the non-coding genome in cardiovascular diseases is increasing, which shows the issue's importance. In this study, the molecular regulation of HIF-1 by miRNAs is considered to improve therapeutic approaches in clinical diagnoses of cardiovascular diseases.

Citing Articles

Medioresinol from Eucommiae cortex improves myocardial infarction-induced heart failure through activation of the PI3K/AKT/mTOR pathway: A network analysis and experimental study.

Qin X, Liu X, Guo C, Huang L, Xu Q PLoS One. 2024; 19(9):e0311143.

PMID: 39331625 PMC: 11433142. DOI: 10.1371/journal.pone.0311143.

References

Abkhooie L, Sarabi M, Kahroba H, Eyvazi S, Montazersaheb S, Tarhriz V . Potential Roles of MyomiRs in Cardiac Development and Related Diseases. Curr Cardiol Rev. 2020; 17(4):e010621188335. PMC: 8762156. DOI: 10.2174/1573403X16999201124201021. View

Hashimoto T, Shibasaki F . Hypoxia-inducible factor as an angiogenic master switch. Front Pediatr. 2015; 3:33. PMC: 4408850. DOI: 10.3389/fped.2015.00033. View

Solly E, Dimasi C, Bursill C, Psaltis P, Tan J . MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis. J Clin Med. 2019; 8(12). PMC: 6947565. DOI: 10.3390/jcm8122199. View

Martin-Puig S, Tello D, Aragones J . Novel perspectives on the PHD-HIF oxygen sensing pathway in cardioprotection mediated by IPC and RIPC. Front Physiol. 2015; 6:137. PMC: 4438228. DOI: 10.3389/fphys.2015.00137. View

Ahmad A, Ahmad S, Malcolm K, Miller S, Hendry-Hofer T, Schaack J . Differential regulation of pulmonary vascular cell growth by hypoxia-inducible transcription factor-1α and hypoxia-inducible transcription factor-2α. Am J Respir Cell Mol Biol. 2013; 49(1):78-85. PMC: 3727885. DOI: 10.1165/rcmb.2012-0107OC. View

Serocki M, Bartoszewska S, Janaszak-Jasiecka A, Ochocka R, Collawn J, Bartoszewski R . miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. Angiogenesis. 2018; 21(2):183-202. PMC: 5878208. DOI: 10.1007/s10456-018-9600-2. View

Fathi M, Gharakhanlou R, Rezaei R . The Changes of Heart miR-1 and miR-133 Expressions following Physiological Hypertrophy Due to Endurance Training. Cell J. 2020; 22(Suppl 1):133-140. PMC: 7481891. DOI: 10.22074/cellj.2020.7014. View

Liu M, Galli G, Wang Y, Fan Q, Wang Z, Wang X . Novel Therapeutic Targets for Hypoxia-Related Cardiovascular Diseases: The Role of HIF-1. Front Physiol. 2020; 11:774. PMC: 7375027. DOI: 10.3389/fphys.2020.00774. View

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

10.

Lu Y, Thavarajah T, Gu W, Cai J, Xu Q . Impact of miRNA in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018; 38(9):e159-e170. PMC: 6795547. DOI: 10.1161/ATVBAHA.118.310227. View

11.

Bouthelier A, Aragones J . Role of the HIF oxygen sensing pathway in cell defense and proliferation through the control of amino acid metabolism. Biochim Biophys Acta Mol Cell Res. 2020; 1867(9):118733. DOI: 10.1016/j.bbamcr.2020.118733. View

12.

Greco S, Fasanaro P, Castelvecchio S, DAlessandra Y, Arcelli D, Di Donato M . MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes. 2012; 61(6):1633-41. PMC: 3357263. DOI: 10.2337/db11-0952. View

13.

Cummins E, Keogh C, Crean D, Taylor C . The role of HIF in immunity and inflammation. Mol Aspects Med. 2016; 47-48:24-34. DOI: 10.1016/j.mam.2015.12.004. View

14.

Al-Kafaji G, Al-Muhtaresh H, Salem A . Expression and clinical significance of miR-1 and miR-133 in pre-diabetes. Biomed Rep. 2021; 14(3):33. PMC: 7873585. DOI: 10.3892/br.2021.1409. View

15.

Perez-Cremades D, Chen J, Assa C, Feinberg M . MicroRNA-mediated control of myocardial infarction in diabetes. Trends Cardiovasc Med. 2022; 33(4):195-201. PMC: 9288556. DOI: 10.1016/j.tcm.2022.01.004. View

16.

Li X, Zhang Q, Nasser M, Xu L, Zhang X, Zhu P . Oxygen homeostasis and cardiovascular disease: A role for HIF?. Biomed Pharmacother. 2020; 128:110338. DOI: 10.1016/j.biopha.2020.110338. View

17.

John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D . Human MicroRNA targets. PLoS Biol. 2004; 2(11):e363. PMC: 521178. DOI: 10.1371/journal.pbio.0020363. View

18.

Wang H, Sugimoto K, Lu H, Yang W, Liu J, Yang H . HDAC1-mediated deacetylation of HIF1α prevents atherosclerosis progression by promoting miR-224-3p-mediated inhibition of FOSL2. Mol Ther Nucleic Acids. 2021; 23:577-591. PMC: 7815465. DOI: 10.1016/j.omtn.2020.10.044. View

19.

de Gonzalo-Calvo D, van der Meer R, Rijzewijk L, Smit J, Revuelta-Lopez E, Nasarre L . Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Sci Rep. 2017; 7(1):47. PMC: 5428350. DOI: 10.1038/s41598-017-00070-6. View

20.

Tekin D, Dursun A, Xi L . Hypoxia inducible factor 1 (HIF-1) and cardioprotection. Acta Pharmacol Sin. 2010; 31(9):1085-94. PMC: 4002308. DOI: 10.1038/aps.2010.132. View